Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Mechlorethamine
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Helsinn Publishes New Data Evaluating Chlormethine Gel’s Mode Of Action In Dermatology And Therapy
Details : VALCHLOR® (mechlorethamine) gel 0.016% is indicated for the topical treatment of Stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL) in patients who have received prior skin-directed therapy.
Product Name : Ledaga
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 18, 2022
Lead Product(s) : Mechlorethamine
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mechlorethamine
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LEDAGA® (chlormethine) gel is an alkylating drug indicated for the topical treatment of MF-CTCL in adult patients. LEDAGA® is a gel which is applied topically once a day.
Product Name : Ledaga
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 21, 2022
Lead Product(s) : Mechlorethamine
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mechlorethamine
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Recordati Rare Diseases
Deal Size : Inapplicable
Deal Type : Inapplicable
Deep Phenotyping of Cutaneous T Cell Lymphoma, Type Mycosis Fungoides
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 31, 2022
Lead Product(s) : Mechlorethamine
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Recordati Rare Diseases
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mechlorethamine
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Helsinn Advanced Synthesis
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, the registeration, distribution, promotion, market and sell LEDAGA® (chlormethine gel) in Australia, Asia and the Middle East* as a topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (“MF-CTCL”) in adults.
Product Name : Ledaga
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 09, 2022
Lead Product(s) : Mechlorethamine
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Helsinn Advanced Synthesis
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Mechlorethamine
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Kyowa Kirin
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Helsinn will grant Kyowa Kirin an exclusive license to distribute, promote, market, and sell VALCHLOR® in China. Helsinn will be responsible for clinical development, regulatory activities, and the supply of VALCHLOR® for commercial use in China.
Product Name : Ledaga
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 12, 2020
Lead Product(s) : Mechlorethamine
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Kyowa Kirin
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Mechlorethamine
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Johnson & Johnson
Deal Size : Inapplicable
Deal Type : Inapplicable
Valchlor in the Treatment of Lichen Planopilaris
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 31, 2018
Lead Product(s) : Mechlorethamine
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Johnson & Johnson
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mechlorethamine
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Rochester General Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Mechlorethamine Induced Contact Dermatitis Avoidance Study
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 20, 2017
Lead Product(s) : Mechlorethamine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Rochester General Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mechlorethamine
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Johnson & Johnson
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 20, 2017
Lead Product(s) : Mechlorethamine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Johnson & Johnson
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mechlorethamine
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Johnson & Johnson
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 29, 2016
Lead Product(s) : Mechlorethamine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Johnson & Johnson
Deal Size : Inapplicable
Deal Type : Inapplicable